Explore the latest advancements and emerging therapies for multiple myeloma approved or under development in Europe. This guide details innovative treatments, including cell therapies like Carvykti and drug combinations such as Sarclisa, which are transforming the landscape of managing this disease. Stay informed about marketing authorisations and recommendations from agencies like the EMA, crucial for patients and healthcare professionals. Discover how these new options are improving the quality of life and outlook for multiple myeloma patients across the European Union.
Pomalidomide is an established treatment for multiple myeloma in Europe, particularly for patients with relapsed or refractory disease. Its efficacy in combination with dexamethasone offers a vital option for those who have not responded to previous therapies, significantly improving prognosis and quality of life.
Received marketing authorisation in EU
Ixazomib (Ninlaro) represents a significant advancement in multiple myeloma treatment as the first oral proteasome inhibitor. Its approval in 2015 and efficacy in combination with other therapies have improved progression-free survival for patients who have received prior treatments. This drug offers a crucial therapeutic option for managing the disease in Europe.
Carvykti has received European Commission approval for the treatment of adult patients with relapsed and refractory multiple myeloma. This BCMA-targeted CAR-T therapy provides a crucial new option for patients who have received at least one prior line of therapy, including those as early as first relapse.
Received conditional marketing authorisation in Europe
Talquetamab represents a significant advancement in multiple myeloma treatment in Europe, having received conditional marketing authorization from the European Commission. This bispecific antibody offers a new therapeutic option for patients with relapsed and refractory multiple myeloma, demonstrating response rates over 70% in clinical trials. Its innovative mechanism of action, targeting GPRC5D, establishes it as a crucial therapy for patients who have exhausted other treatment lines.
First CAR T cell immunotherapy approved in EU
(+2)
Abecma has demonstrated a significant improvement in progression-free survival for patients with relapsed or refractory multiple myeloma, extending this period three times longer than standard treatments. Its approval in Europe offers a crucial new therapeutic option for patients who have exhausted other lines of treatment, marking a milestone in the fight against this disease.
All the rankings you can imagine
Thousands of verified votes to discover the best. Your vote here counts
Approved for smouldering multiple myeloma
(+1)
Daratumumab has shown remarkable efficacy in treating multiple myeloma, with an 84% progression-free survival at 4 years when combined with standard treatment. This drug significantly improves complete response rates and minimal residual disease negativity, offering superior outcomes compared to standard treatment alone.
Approved for newly diagnosed multiple myeloma in EU
(+4)
Isatuximab represents a significant advancement in multiple myeloma treatment by directly targeting malignant cells via the CD38 receptor. Its triple mechanism of action, including direct cell destruction, immune system enhancement, and exposing cells for elimination, offers a robust therapeutic strategy for patients in Europe.
Synergistic anti-tumor activity
(+4)
Iberdomide represents a significant advancement in the treatment of multiple myeloma, particularly for patients with relapsed or refractory disease. Its mechanism of action as a cereblon E3 ligase modulator (CELMoD) offers a powerful new therapeutic strategy. Clinical trial data, such as from EXCALIBER-RRMM, have demonstrated improvements in minimal residual disease negativity and meaningful clinical activity.
Approved by the European Commission
(+1)
Elotuzumab (Empliciti) has been approved in Europe for the treatment of multiple myeloma, offering a new therapeutic option. Its combination with pomalidomide and dexamethasone has shown to significantly improve progression-free survival in patients with relapsed and refractory multiple myeloma.
Approved for use in Europe as a second-line treatment
Bortezomib is a foundational treatment for multiple myeloma, acting as a proteasome inhibitor that induces apoptosis in cancer cells. Its approval and widespread use in combination with other therapies establish it as a crucial therapeutic option in Europe for patients with this disease.
Approved for previously untreated multiple myeloma patients
(+1)
Lenalidomide is a cornerstone treatment for multiple myeloma in Europe, both in combination with dexamethasone and as post-transplant maintenance therapy. Its effectiveness in improving patient survival and quality of life makes it a key therapeutic option. This drug has proven to be a pillar in the management of this disease, offering significant benefits across various stages of treatment.
Carfilzomib is an innovative treatment for multiple myeloma in Europe, particularly for patients with relapsed or refractory disease. Its mechanism of action as a second-generation proteasome inhibitor provides an effective therapeutic option for those who have received previous treatments.
The methodology for creating this ranking focuses on gathering and presenting information about the most recent and relevant multiple myeloma treatments that have received approval or recommendation in Europe. Our goal is to offer a clear and concise overview of emerging therapeutic options.